Adverum Biotech 筹集了 1.275 亿美元用于基因治疗。 Adverum Biotech raises $127.5M for gene therapy.

Adverum Biotechnologies 正在进行私募，筹集 1.275 亿美元，将用于投资其临床阶段的基因治疗项目。 Adverum Biotechnologies is conducting a private placement to raise $127.5 million, which will be used to invest in their clinical-stage gene therapy programs. 控股和投资公司诺和控股 (Novo Holdings) 和诺和诺德 (Novo Nordisk) 正以 110 亿美元收购三个灌装厂。 Novo Holdings, a holding and investment company, and Novo Nordisk are acquiring three fill-finish sites for $11 billion. 这是 Novo Holdings 收购合同制药商 Catalent 的一部分。 This comes as a part of Novo Holdings' acquisition of contract drugmaker Catalent. 这些交易旨在扩大广受欢迎的减肥药 Wegovy 的产能，并提高诺和诺德从 2026 年起的灌装能力。 These deals aim to expand capacity for popular weight-loss drug Wegovy and increase Novo Nordisk's filling capacity from 2026 onwards.